(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 November 2015 (26.11.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/179742 A1

(51) International Patent Classification:
A61K 31/712 (2006.01) *C12N 15/113* (2010.01)
C07K 19/00 (2006.01) *A61K 47/48* (2006.01)

(21) International Application Number:
PCT/US2015/032142

(22) International Filing Date:
22 May 2015 (22.05.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/002,296 23 May 2014 (23.05.2014) US

(71) Applicant: **GENZYME CORPORATION** [US/US]; 500 Kendall Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **WEEDEN, Timothy E.**; c/o SANOFI, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). **NELSON, Carol A.**; 18 Maple Street, Westford, Massachusetts 01996 (US). **WENTWORTH, Bruce M.**; 27 Ridge Road, Northborough, Massachusetts 01532 (US). **CLAYTON, Nicholas P.**; c/o SANOFI, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). **LEGER, Andrew**; c/o SANOFI, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US).

(74) Agents: **TOUSIGNANT, Jennifer D.** et al.; Sanofi U.S., 55 Corporate Drive, Mail Code: 55A - 505A, Bridgewater, New Jersey 08807 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*


Published:

— *with international search report (Art. 21(3))*

[Continued on next page]

(54) Title: MULTIPLE OLIGONUCLEOTIDE MOIETIES ON PEPTIDE CARRIER

FIGURE 3



(57) Abstract: The present disclosure relates to antisense oligonucleotides (AONs), such as phosphorodiamidate morpholino oligonucleotides (PMOs). The present disclosure further relates to the conjugation of multiple PMOs to cationic cell penetrating peptides (CPPs) to enhance the uptake of PMOs into skeletal and cardiac muscle cells.

WO 2015/179742 A1

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*